Ticker Details
Akebia Therapeutics, Inc. Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology.
IPO Date:	March 24, 2018
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$377.71M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.13 | 3.50%
Avg Daily Range (30 D):	$0.03 | 1.90%
Avg Daily Range (90 D):	$0.04 | 2.66%

Institutional Daily Volume
Avg Daily Volume:	2.81M
Avg Daily Volume (30 D):	2.24M
Avg Daily Volume (90 D):	2.62M

Trade Size
Avg Trade Size (Sh.):	316
Avg Trade Size (Sh.) (30 D):	256
Avg Trade Size (Sh.) (90 D):	303

Institutional Trades
Total Institutional Trades:	1,032
Avg Institutional Trade:	$1.63M
Avg Institutional Trade (30 D):	$1.81M
Avg Institutional Trade (90 D):	$1.45M
Avg Institutional Trade Volume:	.48M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.55M
Avg Closing Trade (30 D):	$1.92M
Avg Closing Trade (90 D):	$1.43M
Avg Closing Volume:	478.33K

News

Feb 19, 2026 @ 1:00 PM Akebia Therapeutics to Report Fourth Quarter and F... Source: Na

Feb 4, 2026 @ 1:00 PM Akebia Therapeutics to Present at the Guggenheim E... Source: Not Specified

Dec 1, 2025 @ 2:43 PM Why Is Small-Cap Q32 Bio Stock Soaring On Monday? Source: Vandana Singh

Nov 6, 2025 @ 11:30 PM Vafseo® (vadadustat) Dialysis Dependent Patient... Source: Akebia Therapeutics

Jul 8, 2025 @ 12:00 PM Akebia Therapeutics to Present at the H.C. Wainwri... Source: Mercedes Carrasco

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-.02	$-.05	$-.02
Diluted EPS	$-.02	$-.05	$-.02
Revenue	$236.2M	$57.62M	$236.2M
Gross Profit	$196.73M	$45.09M	$196.73M
Net Income / Loss	$-5.35M	$-12.24M	$-5.35M
Operating Income / Loss	$23.5M	$-8.55M	$23.5M
Cost of Revenue	$39.46M	$12.54M	$39.46M
Net Cash Flow	$132.99M	$18.4M	$132.99M
PE Ratio